168 related articles for article (PubMed ID: 31519431)
21. Long-term efficacy of standardised specific subcutaneous immunotherapy in children with persistent allergic rhinitis due to multiple allergens including house dust mites.
Song Y; Long J; Wang T; Xie J; Wang M; Tan G
J Laryngol Otol; 2018 Mar; 132(3):230-235. PubMed ID: 29374499
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of a once-daily sublingual immunotherapy without escalation regimen in house dust mite-induced allergic rhinitis.
Mun SJ; Shin JM; Han DH; Kim JW; Kim DY; Lee CH; Min YG; Rhee CS
Int Forum Allergy Rhinol; 2013 Mar; 3(3):177-83. PubMed ID: 23044892
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of specific immunotherapy on house dust mite-induced allergic rhinitis in China.
Peng H; Li CW; Lin ZB; Li TY
Otolaryngol Head Neck Surg; 2013 Jul; 149(1):40-6. PubMed ID: 23569202
[TBL] [Abstract][Full Text] [Related]
24. [Intradermal immunotherapy with low-dose house dust mite allergens in patients with allergic rhinitis: A proof-of-concept study].
Vieira-Hernández A; Capriles-Hulett A; Sánchez-Borges M; Fabiano F; Albarrán-Barrios C
Rev Alerg Mex; 2018; 65(1):41-51. PubMed ID: 29723940
[TBL] [Abstract][Full Text] [Related]
25. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of sublingual immunotherapy in Asian children.
Park IH; Hong SM; Lee HM
Int J Pediatr Otorhinolaryngol; 2012 Dec; 76(12):1761-6. PubMed ID: 22959336
[TBL] [Abstract][Full Text] [Related]
27. The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study.
Tu Y; Zhang H; Zhao L; Jin P; Zi X; Li T; Shi L; Zhi L
J Laryngol Otol; 2019 Mar; 133(3):213-219. PubMed ID: 30674357
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.
Bergmann KC; Demoly P; Worm M; Fokkens WJ; Carrillo T; Tabar AI; Nguyen H; Montagut A; Zeldin RK
J Allergy Clin Immunol; 2014 Jun; 133(6):1608-14.e6. PubMed ID: 24388010
[TBL] [Abstract][Full Text] [Related]
29. A Three-Year Course of House Dust Mite Sublingual Immunotherapy Appears Effective in Controlling the Symptoms of Allergic Rhinitis.
Novakova SM; Novakova PI; Yakovliev PH; Staevska MT; Mateva NG; Dimcheva TD; Peichev JL
Am J Rhinol Allergy; 2018 May; 32(3):147-152. PubMed ID: 29649893
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy evaluation of specific immunotherapy with standardized house dust mite allergen preparation for allergic rhinitis].
Zhou J; He Y; Zeng X; Li Z; Pan F; Chen Y; Li Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Jun; 26(11):487-9. PubMed ID: 22934334
[TBL] [Abstract][Full Text] [Related]
31. Intralymphatic immunotherapy.
Senti G; Johansen P; Kündig TM
Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):537-43. PubMed ID: 19680119
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of sublingual immunotherapy for house dust mite allergic rhinitis.
Cingi C; Bayar Muluk N; Ulusoy S; Acar M; Şirin S; Çobanoğlu B; Birdane L; Kalaycık Ç; Çakır BÖ; Oğhan F; Aynacı S; Erdoğmuş N; Yıldırım Ö; Şahin E; Bulut F; Aksoy MA; Türe N; Bal C
Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3341-6. PubMed ID: 25516223
[TBL] [Abstract][Full Text] [Related]
33. Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment.
de Bot CM; Moed H; Berger MY; Röder E; de Groot H; de Jongste JC; van Wijk RG; van der Wouden JC
BMC Fam Pract; 2008 Oct; 9():59. PubMed ID: 18937864
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis.
Timm K; Mueller RS; Nett-Mettler CS
Vet Dermatol; 2018 Apr; 29(2):123-e49. PubMed ID: 29327474
[TBL] [Abstract][Full Text] [Related]
35. [Comparison study of subcutaneous immunotherapy and sublingual immunotherapy in patients with allergic rhinitis].
You SH; Qin XY; Xu C; Qiu X; Luan ZL; Jia HX; Wang HT
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 May; 30(9):689-693. PubMed ID: 29771014
[No Abstract] [Full Text] [Related]
36. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
Richards JR; Stumpf JL
Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
[TBL] [Abstract][Full Text] [Related]
37. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells.
O'Hehir RE; Gardner LM; de Leon MP; Hales BJ; Biondo M; Douglass JA; Rolland JM; Sandrini A
Am J Respir Crit Care Med; 2009 Nov; 180(10):936-47. PubMed ID: 19696440
[TBL] [Abstract][Full Text] [Related]
38. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy.
Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
Asian Pac J Allergy Immunol; 2013 Sep; 31(3):233-41. PubMed ID: 24053706
[TBL] [Abstract][Full Text] [Related]
39. IVN201--therapy with a construct containing functional fusion peptides.
Rose H
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():319-27; discussion 327-8. PubMed ID: 20799476
[TBL] [Abstract][Full Text] [Related]
40. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
